Nancy Stuart - 28 Jan 2022 Form 4 Insider Report for CONCERT PHARMACEUTICALS, INC.

Reporting relationship: Chief Operating Officer
Issuer ticker: N/A
Reported as of: 28 Jan 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Feb 2022, 15:06:07 UTC
Prior SEC filing: 07 Jan 2022
Next SEC filing: 16 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ Jeffrey A. Munsie, attorney-in-fact

Key filing fact

Nancy Stuart filed Form 4 for CONCERT PHARMACEUTICALS, INC. on 01 Feb 2022.

Key facts

This page summarizes Nancy Stuart's Form 4 filing for CONCERT PHARMACEUTICALS, INC..
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 01 Feb 2022, 15:06.

Change

Previous filing in this sequence was filed on 07 Jan 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CNCE transaction

Common Stock

Award

Transaction value
Shares: +99,000
Change %: +58%
Price
Shares after: 269,386
Date: 28 Jan 2022
Ownership: Direct
Footnotes: F1, F2

CNCE transaction

Common Stock

Award

Transaction value
Shares: +21,400
Change %: +7.9%
Price
Shares after: 290,786
Date: 28 Jan 2022
Ownership: Direct
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. These RSUs vest in equal annual installments over a three-year period measured from the date of grant. The amount listed represents the maximum number of shares of Common Stock of the Issuer that may be delivered pursuant to the grant.

Footnote F2

Not applicable.

Footnote F3

Represents a grant of RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. These RSUs vest one business day after the date on which the Food and Drug Administration notifies the Issuer that it has accepted for filing a New Drug Application for CTP-543, provided that the date of acceptance is on or before a certain date in 2023. The amount listed represents the maximum number of shares that may be delivered pursuant to the grant.